GHK-Cu

GHK-Cu is a naturally occurring copper complex tied to collagen synthesis and used off-label mainly for skin rejuvenation, hair growth, and wound healing; in 24 captured community reports, 15 focus on skin and the vast majority rate those outcomes positive. Clinician-tier guidance runs from 200 mcg to 1.5 mg subcutaneously once or twice daily, continuously or in 4–8 week cycles, though community logs show no consistent pattern and sources diverge on frequency and cycle length. The evidence base is thinner than the discourse suggests; most exploratory indications lack posted human results.

GHK-Cu

Research Evidence

Evidence shape

The clinical evidence for GHK-Cu is limited. Mapped across three indications, the human data consist of just two thin, exploratory trials—a Phase 4 study in facial skin laxity and an active trial in punch-biopsy wound healing—and neither has posted results, so the entire evidence base rests on single-trial indications without any robust published clinical outcomes. The remainder is animal-only preclinical work, leaving the peptide studied but not at scale.

Depthhow much
2 registered trials
1 completed · 1 recruiting / active
Breadthhow many areas
3 indications mapped
2 thin / exploratory · 1 animal-only · 2 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 4
Breadth and depth26 rows captured
Human
direct clinical signal
2
Animal
translational support
12
In vitro
mechanistic support
12
HighMediumLow

Anecdotal efficacy

Price

1
US
100 mg
$1.00
$0.01/mg
2
UK
2400 mg
$40.03
$0.013/mg
3
unknown
500 mg
$12.81
$0.023/mg
4
HK
1000 mg
$50.00
$0.05/mg
5
US
1000 mg
$104.50
$0.1/mg
6
US
1000 mg
$170.00
$0.17/mg

price offers can be sorted by column

1-6 of 149

Dosing & Protocol

How GHK-Cu is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 1
Typical dose
No quantified dose captured for this tier.
Timing
unspecified
Cycle
unspecified

1 completed trial identified; trial dosing not reliably extracted from registry data.

1 source
Clinician practice
Doctor & published-protocol guidance · n = 3
Starting dose
200 µg200 µg – 1.5 mg
250 µg
500 µg
1 mg
Frequency
daily
Timing
unspecified
Route
subQ
Cycle
unspecified

Clinician protocols dose 200 µg–1.5 mg daily subQ (3 sources).

3 sources
Anecdotal
Community-reported real-world use · n = 19
Typical dose
No quantified dose captured for this tier.

No structured protocol details captured for this tier yet.

Community reports show uniformly positive feedback for skin rejuvenation (12 reports), wound healing (4 reports), and hair growth (3 reports). Specific dose information was not consistently reported in community discussions.

Peptide Deep Dive

Peptide Deep Dive is not projected for this peptide yet.

Peptide feedback

0 forum replies

Live community discussion for GHK-Cu, shown here in the site layout and continued on the TVR forum.

Add feedback

No peptide feedback yet

Start the peptide feedback thread on the TVR forum.